K145 is a selective, substrate-competitive, and orally active sphingosine kinase-2 (SphK2) inhibitor with potent antitumor activity; it induces apoptosis in cancer cells, inhibits tumor growth in vitro and in vivo, and suppresses phosphorylation of ERK and Akt without significantly affecting ceramide levels.